[Broncaspin in respiratory diseases in pediatrics. Clinical contribution]

Minerva Med. 1981 Feb 28;72(7):417-22.
[Article in Italian]

Abstract

Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Aspirin / analogs & derivatives*
  • Aspirin / therapeutic use
  • Bronchitis / drug therapy
  • Bronchopneumonia / drug therapy
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Cough / drug therapy
  • Dyspnea / drug therapy
  • Fever / drug therapy
  • Humans
  • Infant
  • Laryngitis / drug therapy
  • Pharyngitis / drug therapy
  • Respiratory Tract Diseases / drug therapy*
  • Tracheitis / drug therapy

Substances

  • Aspirin
  • guacetisal